Hematopoietic Stem Cell TransplantationTransplantation, HomologousMultiple MyelomaStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTransplantation ChimeraStem CellsTreatment OutcomeBone Marrow TransplantationMyeloablative AgonistsGraft vs Leukemia EffectBusulfanRemission InductionTissue DonorsRecurrenceVidarabineGraft vs Tumor EffectMelphalanGraft SurvivalHistocompatibility TestingLymphocyte TransfusionImmunosuppressive AgentsCombined Modality TherapyLeukemiaRetrospective StudiesLeukemia, Myeloid, AcuteSalvage TherapyDisease-Free SurvivalSurvival AnalysisHematopoietic Stem CellsSiblingsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCord Blood Stem Cell TransplantationWhole-Body IrradiationSurvival RateCytomegalovirus InfectionsMinor Histocompatibility AntigensAntineoplastic Combined Chemotherapy ProtocolsLymphocyte DepletionLiver TransplantationMyelodysplastic SyndromesNeoplasm, ResidualAntilymphocyte SerumVirus ActivationPrecursor Cell Lymphoblastic Leukemia-LymphomaHistocompatibilityCyclophosphamideTime FactorsChimerismHematopoietic Stem Cell MobilizationHepatic Veno-Occlusive DiseaseAntineoplastic AgentsThalidomideBoronic AcidsMesenchymal Stem Cell TransplantationPrognosisT-LymphocytesPyrazinesCytomegalovirusFollow-Up StudiesAcute DiseaseHematologic DiseasesPrimary MyelofibrosisCell TransplantationAnemia, AplasticKidney TransplantationAntigens, CD34HLA AntigensEmbryonic Stem CellsMyeloma ProteinsLeukemia, Myeloid, Accelerated PhaseAntibodies, NeoplasmCytarabineBone MarrowTransplantation ImmunologyImmunosuppressionBenzamidesLymphoproliferative DisordersRoseolovirus InfectionsImmunocompromised HostLeukemia, MyeloidHodgkin DiseaseAdult Stem CellsLymphoma, Non-HodgkinFusion Proteins, bcr-ablPyrimidinesBone Marrow CellsGranulocyte Colony-Stimulating FactorFatal OutcomeReceptors, Purinergic P2X5Flow CytometryNuclear FamilyGraft RejectionInfectionPiperazinesAntibodies, Monoclonal